Myriad Genetics announced on June 2 that Raj Jampa will become its new Chief Technology Officer, according to the company's [GlobeNewswire release](https://www.globenewswire.com/news-release/2026/06/02/Myriad-Genetics-Names-Raj-Jampa-as-New-Chief-Technology-Officer.html) reported by Yahoo Finance. The appointment lands at a moment when Myriad is trying to consolidate a sprawling portfolio of molecular diagnostic products onto a unified data and inference platform, and when the wider healthcare sector is reorganizing around AI assisted interpretation of genomic, oncology, and prenatal results.
The structural detail matters more than the individual hire. Myriad already had a CIO, and Jampa's CTO role is being defined to own product engineering, the underlying data platform, clinical informatics, and the AI capabilities that increasingly drive both throughput and clinical accuracy. That mirrors the pattern we have been watching all spring in the [CIO.com Movers and Shakers roundup](https://www.cio.com/article/230613/new-cio-appointments.html), where titles like CIDO, CDIO, and CTPO have proliferated and the line between IT and product engineering has effectively dissolved at regulated companies. May alone saw a wave of similar restructurings at Northrop Grumman, McDonald's, Autodesk, Verkada, and Alteryx.
For technology leaders selling into healthcare, the buying motion is shifting. A year ago, a diagnostics company would have routed a platform purchase through a CIO who managed Epic integrations and vendor relationships. Today the same purchase is increasingly evaluated by a CTO who is building, not buying, and who treats every external vendor as a make or buy decision against an internal engineering team. The implication for our go to market is that pure IT focused pitches lose ground. Buyers want technical depth, API quality, model performance benchmarks, and clear answers on data residency and HIPAA aligned inference.
The internal implication is just as important. If Myriad's structure becomes the norm, our own engineering organizations need to be ready to absorb responsibilities that used to sit in IT. Identity, access management, vendor SaaS sprawl, and compliance posture all start to land on the CTO desk. Most engineering orgs are not staffed for that. Platform engineering teams have to expand beyond developer experience to include enterprise IT primitives, and security has to move from a gating function to an embedded discipline.
There is also a recruiting signal. The pace of senior tech hires in healthcare and adjacent regulated industries has accelerated, and the candidate pool is tightening. Anyone with a track record of running both clinical software and ML platforms is fielding multiple offers. If we are planning to fill a similar role this year, we need to move faster on offers, lean harder on equity, and expect to compete with healthcare incumbents that historically did not pay Silicon Valley comp.
The Myriad hire on its own would be a small data point. Combined with the steady drumbeat of CTO and CIDO appointments through April and May, it is part of a broader rewiring. Boards are deciding that the people running technology now also need to run the product. For us, the question is whether our own title structure, reporting lines, and scope match where our largest customers are heading. If not, this is the quarter to fix it.
A few practical implications for our own planning. First, when we map the buying committee at a healthcare or life sciences account, we should now assume the CTO is a primary technical decision maker, not a coach to the CIO. Sales engineering needs to be staffed accordingly, with engineers who can hold a real architecture conversation about inference pipelines, model evaluation, and clinical validation. Second, partnerships and integrations matter more than ever. A CTO who is consolidating platforms is also consolidating vendor relationships. The companies that already have native integrations into the dominant electronic health record systems and the major cloud ML platforms will have an inside track in 2026 procurement cycles. Third, watch the talent flow. The May CIO.com roundup shows a consistent pattern of senior leaders moving from large enterprises like Kaiser, GE Aerospace, and Carrier into mid sized regulated companies. That talent migration tends to bring vendor preferences and architectural patterns with it. If a former Kaiser executive joins one of our prospects, the technology stack conversation will start from a very different baseline than it would have six months earlier.
Finally, there is the question of internal tempo. Healthcare CTOs are now being asked to ship AI assisted features on the same cadence as consumer software companies, while still meeting clinical validation requirements and regulator expectations. That tension shows up in hiring plans. Expect to see continued demand for ML platform engineers, clinical informatics leads, and security engineers who understand both HIPAA and modern model deployment. If our own hiring funnel is competing for the same candidates, we should be ready to articulate why our environment is the better place to do the work, and back that up with concrete examples of shipped product rather than vague mission statements. The Myriad hire is one data point. The pattern behind it is what matters.
